SLC38A2 and neoplasm: Their study demonstrated that glutamine availability enhances conventional dendritic cell type 1 (cDC1)-mediated activation of cytotoxic CD8+ T cells, inhibits tumor progression, and restores immunotherapy sensitivity, mainly through competitive glutamine uptake via SLC38A2 and downstream FLCN-TFEB signaling.